Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro

Wang,Hong-Gang; Huang,Xiao-Dan; Shen,Peng; Li,Lu-Rong; Xue,Hui-Ting; Ji,Guo-Zhong

doi:10.3892/ijmm.2013.1285

Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro

Authors:
- Hong-Gang Wang
- Xiao-Dan Huang
- Peng Shen
- Lu-Rong Li
- Hui-Ting Xue
- Guo-Zhong Ji
View Affiliations

Affiliations: Institute of Digestive Endoscopy and Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, P.R. China, Department of Gastroenterology, The First People's Hospital of Kunshan, Kunshan, Jiangsu 215300, P.R. China
Published online on: February 22, 2013 https://doi.org/10.3892/ijmm.2013.1285
Pages: 967-974

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we investigated the anticancer effects of sodium butyrate (NaBu) on hepatocellular carcinoma (HCC) cells in vitro. As a histone deacetylase (HDAC) inhibitor, NaBu upregulated Ac-H3 and inhibited HDAC4 protein expression in a time- and dose-dependent manner. MTT assays showed that treatment with NaBu at high concentrations significantly inhibited the growth of various HCC cells. Exposure to NaBu for 24 h induced cell cycle arrest in the SMMC-7721 and HepG2 cells. NaBu also induced the apoptosis of SMMC‑7721 cells. The expression levels of cell cycle- and apoptosis-related proteins were further investigated by western blot analysis using specific antibodies. The results provided a possible mechanism responsible for the inhibitory effects of NaBu on the growth of HCC cells. To further analyze the role of NaBu in cell migration, wound healing and Transwell assays were performed, indicating that NaBu significantly inhibits cell migration/invasion in HCC cells. Transforming growth factor-β1 (TGF-β1)-induced epithelial to mesenchymal transition (EMT) has been associated with tumor cell migration and invasion. The EMT markers, E-cadherin, vimentin and N-cadherin, were regulated by TGF-β1, while NaBu inhibited this process in which HDAC4 and matrix metalloproteinase (MMP)7 may be involved. Based on our findings, we propose that NaBu may be useful as an anticancer drug for HCC therapy.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Tang ZY: Small hepatocellular carcinoma: current status and prospects. Hepatobiliary Pancreat Dis Int. 1:349–353. 2002.PubMed/NCBI
3	Giannelli G, Bergamini C, Fransvea E, Sgarra C and Antonaci S: Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology. 129:1375–1383. 2005. View Article : Google Scholar : PubMed/NCBI
4	Marks PA, Richon VM, Miller T and Kelly WK: Histone deacetylase inhibitors. Adv Cancer Res. 91:137–168. 2004. View Article : Google Scholar : PubMed/NCBI
5	Jeon HW and Lee YM: Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. Mol Cancer Ther. 9:1361–1370. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ahn MY, Kang DO, Na YJ, et al: Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing. Cancer Lett. 325:189–199. 2012. View Article : Google Scholar : PubMed/NCBI
7	Yuan JH, Yang F, Chen BF, et al: The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology. 54:2025–2035. 2011. View Article : Google Scholar : PubMed/NCBI
8	Zhang J, Yang Y, Yang T, et al: microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer. 103:1215–1220. 2010. View Article : Google Scholar : PubMed/NCBI
9	Prasad KN: Butyric acid: a small fatty acid with diverse biological functions. Life Sci. 27:1351–1358. 1980. View Article : Google Scholar : PubMed/NCBI
10	D’Argenio G and Mazzacca G: Short-chain fatty acid in the human colon. Relation to inflammatory bowel diseases and colon cancer. Adv Exp Med Biol. 472:149–158. 1999.PubMed/NCBI
11	Bergman EN: Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev. 70:567–590. 1990.PubMed/NCBI
12	Candido EP, Reeves R and Davie JR: Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 14:105–113. 1978. View Article : Google Scholar : PubMed/NCBI
13	Fung KY, Cosgrove L, Lockett T, Head R and Topping DL: A review of the potential mechanisms for the lowering of colorectal oncogenesis by butyrate. Br J Nutr. 108:820–831. 2012. View Article : Google Scholar : PubMed/NCBI
14	Archer SY, Meng S, Shei A and Hodin RA: p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA. 95:6791–6796. 1998. View Article : Google Scholar : PubMed/NCBI
15	Fung KY, Brierley GV, Henderson S, et al: Butyrate-induced apoptosis in HCT116 colorectal cancer cells includes induction of a cell stress response. J Proteome Res. 10:1860–1869. 2011. View Article : Google Scholar : PubMed/NCBI
16	Davie JR: Inhibition of histone deacetylase activity by butyrate. J Nutr. 133(Suppl 7): 2485S–2493S. 2003.PubMed/NCBI
17	Sun B, Liu R, Xiao ZD and Zhu X: c-MET protects breast cancer cells from apoptosis induced by sodium butyrate. PLoS One. 7:e301432012. View Article : Google Scholar : PubMed/NCBI
18	Tsutsumi T, Ido A, Nakao K, et al: Reciprocal regulation of alpha-fetoprotein and albumin gene expression by butyrate in human hepatoma cells. Gastroenterology. 107:499–504. 1994.PubMed/NCBI
19	Yamamoto H, Fujimoto J, Okamoto E, Furuyama J, Tamaoki T and Hashimoto-Tamaoki T: Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Int J Cancer. 76:897–902. 1998. View Article : Google Scholar : PubMed/NCBI
20	Kaneko F, Saito H, Saito Y, et al: Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate. Int J Oncol. 24:837–845. 2004.PubMed/NCBI
21	Lok GT, Chan DW, Liu VW, et al: Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One. 6:e237902011. View Article : Google Scholar : PubMed/NCBI
22	Dawson MA and Kouzarides T: Cancer epigenetics: from mechanism to therapy. Cell. 150:12–27. 2012. View Article : Google Scholar : PubMed/NCBI
23	Perego P, Zuco V, Gatti L and Zunino F: Sensitization of tumor cells by targeting histone deacetylases. Biochem Pharmacol. 83:987–994. 2012. View Article : Google Scholar : PubMed/NCBI
24	Ganesan A, Nolan L, Crabb SJ and Packham G: Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets. 9:963–981. 2009. View Article : Google Scholar : PubMed/NCBI
25	Quint K, Agaimy A, Di Fazio P, et al: Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch. 459:129–139. 2011. View Article : Google Scholar : PubMed/NCBI
26	Francisco R, Perez-Perarnau A, Cortes C, Gil J, Tauler A and Ambrosio S: Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. Cancer Lett. 318:42–52. 2012. View Article : Google Scholar : PubMed/NCBI
27	Zhang JX, Li DQ, He AR, et al: Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology. 55:1840–1851. 2012. View Article : Google Scholar : PubMed/NCBI
28	Wang J, Kim TH, Ahn MY, et al: Sirtinol, a class III HDAC inhibitor, induces apoptotic and autophagic cell death in MCF-7 human breast cancer cells. Int J Oncol. 41:1101–1109. 2012.PubMed/NCBI
29	Li J, Chen J, Ricupero CL, et al: Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia. Nat Med. 18:783–790. 2012. View Article : Google Scholar : PubMed/NCBI
30	Weems JC, Griesel BA and Olson AL: Class II histone deacetylases downregulate GLUT4 transcription in response to increased cAMP signaling in cultured adipocytes and fasting mice. Diabetes. 61:1404–1414. 2012. View Article : Google Scholar : PubMed/NCBI
31	Reddy SD, Pakala SB, Molli PR, et al: Metastasis-associated protein 1/histone deacetylase 4-nucleosome remodeling and deacetylase complex regulates phosphatase and tensin homolog gene expression and function. J Biol Chem. 287:27843–27850. 2012. View Article : Google Scholar
32	Izutani Y, Yogosawa S, Sowa Y and Sakai T: Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells. Int J Oncol. 40:816–824. 2012.PubMed/NCBI
33	Catalano MG, Fortunati N, Pugliese M, et al: Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. J Clin Endocrinol Metab. 97:E1150–E1159. 2012. View Article : Google Scholar
34	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
35	Yang J and Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
36	Iredale JP: Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 117:539–548. 2007. View Article : Google Scholar : PubMed/NCBI
37	Zeisberg M, Yang C, Martino M, et al: Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem. 282:23337–23347. 2007. View Article : Google Scholar : PubMed/NCBI
38	Nitta T, Kim JS, Mohuczy D and Behrns KE: Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology. 48:909–919. 2008. View Article : Google Scholar : PubMed/NCBI
39	Fransvea E, Angelotti U, Antonaci S and Giannelli G: Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology. 47:1557–1566. 2008. View Article : Google Scholar : PubMed/NCBI
40	Kaimori A, Potter JJ, Choti M, Ding Z, Mezey E and Koteish AA: Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology. 52:1033–1045. 2010. View Article : Google Scholar : PubMed/NCBI
41	Yoshikawa M, Hishikawa K, Marumo T and Fujita T: Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol. 18:58–65. 2007. View Article : Google Scholar
42	Cavallaro U and Christofori G: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 4:118–132. 2004. View Article : Google Scholar : PubMed/NCBI
43	Jovanovic V, Dugast AS, Heslan JM, et al: Implication of matrix metalloproteinase 7 and the noncanonical wingless-type signaling pathway in a model of kidney allograft tolerance induced by the administration of anti-donor class II antibodies. J Immunol. 180:1317–1325. 2008. View Article : Google Scholar
44	Osteen KG, Keller NR, Feltus FA and Melner MH: Paracrine regulation of matrix metalloproteinase expression in the normal human endometrium. Gynecol Obstet Invest. 48(Suppl 1): S2–S13. 1999. View Article : Google Scholar